Teva Launches Generic Lovaza Capsules in the U.S.

A generic equivalent of Lovaza (Omega-3-Acid Ethyl Esters Capsules, USP), has been approved in the U.S. In a statement from Teva Pharmaceutical Industries Ltd., Jerusalem, Israel, the company believes it is first-to-file and thus far is the only company to receive an approval from FDA. It plans to commence shipping immediately.
 
Lovaza Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $1.1 billion in the U.S., according to IMS data as of December 2013.
 
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva is the world’s leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. Its branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics.